Business

HLS Therapeutics Announces New Credit Agreement

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that the company has entered into a new Credit Agreement (the "Agreement") with National Bank of Canada ("National Bank") as administrative agent which provides for committed credit facilities denominated in Canadian dollars of up to CAD $107 million (USD ~$77.5 million).

articleNational Bank Of CanadaAugust 20, 20253/company/national-bank-of-canada/news/hls-therapeutics-announces-new-credit-agreement-1
HLS Therapeutics Announces New Credit Agreement

About this update from National Bank Of Canada

[{"type":"list","items":[{"val":[{"type":"text","content":"CAD $79 million term loan replaces USD $56 million term loan","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"CAD $107 million (~USD $77.5 million) total facility provides enhanced financial flexibility ","length":92,"tagName":"p"}]},{"val":[{"type":"text","content":"CAD-denominated facility reduces FX exposure and lowers interest rate","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":226,"olType":false},{"type":"text","content":"TORONTO, Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that the company has entered into a new Credit Agreement (the "Agreement") with National Bank of Canada ("National Bank") as administrative agent which provides for committed credit facilities denominated in Canadian dollars of up to CAD $107 million (USD ~$77.5 million).","length":547,"tagName":"p"},{"type":"text","content":"National Bank serves as administrative agent and lead arranger, with the Toronto-Dominion Bank, Royal Bank of Canada, and Innovation Federal Credit Union as syndicate members. The Agreement replaced HLS's credit facility with JP Morgan Chase Bank, N.A. which had a maturity date of August 11, 2026. On closing, the proceeds from the new term facility were used to repay the Company's existing credit agreement in full. The new Agreement has a maturity date of August 19, 2029.","length":484,"tagName":"p"},{"type":"text","content":"The Agreement consists of a CAD $79 million term credit facility, a CAD $14 million delayed draw facility and a CAD $14 million revolving credit facility. In addition, HLS can increase facilities further through an uncommitted CAD $40 million accordion facility (subject to Lender agreement).","length":292,"tagName":"p"},{"type":"text","content":"Interest on the Agreement accrues at a rate per month equal to the sum of the Canadian Overnight Repo Rate Average ("CORRA") plus a range of 2.25% to 3.50% depending on the leverage ratio of the Company at the time. Interest rate spreads are 25-50 basis points below the rate in the Company's prior credit agreement, providing improved cash flow thr...

More updates from National Bank Of Canada

National Bank of CanadaRoyal Bank of Canadarevolving credit facilityCNW/ - HLS Therapeutics Inc.pharmaceutical companyCanadian dollarsInnovation Federal Credit UnionCADcredit facilitiesCredit AgreementInterest rateJP Morgan Chase Bank